- Home
- LYRA vs EVAX Comparison
LYRA vs EVAX Comparison
Compare LYRA & EVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LYRA
- EVAX
- Stock Information
- Founded
- LYRA 2005
- EVAX 2008
- Country
- LYRA United States
- EVAX Denmark
- Employees
- LYRA N/A
- EVAX N/A
- Industry
- LYRA Medical/Dental Instruments
- EVAX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LYRA Health Care
- EVAX Health Care
- Exchange
- LYRA Nasdaq
- EVAX Nasdaq
- Market Cap
- LYRA 15.0M
- EVAX 15.1M
- IPO Year
- LYRA 2020
- EVAX 2021
- Fundamental
- Price
- LYRA $7.95
- EVAX $2.72
- Analyst Decision
- LYRA Buy
- EVAX Strong Buy
- Analyst Count
- LYRA 2
- EVAX 2
- Target Price
- LYRA $16.00
- EVAX $10.00
- AVG Volume (30 Days)
- LYRA 91.5K
- EVAX 104.7K
- Earning Date
- LYRA 08-13-2025
- EVAX 08-13-2025
- Dividend Yield
- LYRA N/A
- EVAX N/A
- EPS Growth
- LYRA N/A
- EVAX N/A
- EPS
- LYRA N/A
- EVAX N/A
- Revenue
- LYRA $1,185,000.00
- EVAX $3,293,000.00
- Revenue This Year
- LYRA N/A
- EVAX N/A
- Revenue Next Year
- LYRA $139.18
- EVAX N/A
- P/E Ratio
- LYRA N/A
- EVAX N/A
- Revenue Growth
- LYRA N/A
- EVAX 2555.64
- 52 Week Low
- LYRA $3.81
- EVAX $1.20
- 52 Week High
- LYRA $37.50
- EVAX $17.75
- Technical
- Relative Strength Index (RSI)
- LYRA 41.08
- EVAX 58.89
- Support Level
- LYRA $7.77
- EVAX $2.49
- Resistance Level
- LYRA $8.67
- EVAX $2.71
- Average True Range (ATR)
- LYRA 0.45
- EVAX 0.18
- MACD
- LYRA -0.03
- EVAX 0.01
- Stochastic Oscillator
- LYRA 11.32
- EVAX 72.43
About LYRA Lyra Therapeutics Inc.
Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioabsorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.
About EVAX Evaxion Biotech
Evaxion AS is in the field of oncology. It used the AI-Immunology platform.